FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PRZYBYL ARTHUR						2. Issuer Name <b>and</b> Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
PRZYE	SYL AK.		ANIP ]									Director		10% Owner		wner					
	PHARMA	ACEUTICALS, I	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/28/2020						X	Office below			Other (below)	specify				
210 MAI	N STREE																				
(Street) BAUDETTE MN 56623						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Form filed by One Reporting Person Form filed by More than One Reporting				on		
(City)	(S	tate) (2	Zip)												Perso	on					
		Table	I - No	n-Deriva	tive S	Secu	ritie	s Acq	uired,	Dis	posed of	, or E	Bene	ficiall	y Own	ed					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution		ution y	Date,		4. Securitie Disposed C le (Instr. 5)		es Acquired (A) or Of (D) (Instr. 3, 4 ar		A) or 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) (D)	A) or Price		Transa	action(s) 3 and 4)			(1130.14)				
Common Stock 03/28/2					2020				F <sup>(1)</sup>		4,204	D		\$37.76	198,385			D			
Common Stock 03/31/2					2020				F <sup>(2)</sup>		2,679	D		\$40.74	4 195,706			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Date (Month/Day/Yea		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)				
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amo or Num of Shar	nber							

## **Explanation of Responses:**

- 1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 9,320 shares of restricted stock, which was previously reported.
- 2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,938 shares of restricted stock, which was previously reported.

/s/ Arthur Przybyl

03/31/2020

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.